San Francisco – Tokai Pharmaceuticals is a case study in how not to do drug development.
A company, founded in 2004, with a novel prostate cancer drug has taken 10 years to make it to phase II drug development while competitors such as Medivation and Johnson & Johnson have brought similar new drugs to market in multiple prostate cancer indications.
At ASCO GU this week (Abstract 71), Tokai reported part 1 of their phase 2 ARMOR2 trial with reformulated galeterone (TOK-001) in men with prostate cancer at various stages of the disease in a poster. Part 2 of the study will enrol 136 patients with a once daily dose of 2550 mg.
Subscribers to Premium Content can read below an analysis of some of the challenges that Tokai Pharmaceuticals faces, which raise the question of whether galeterone will in fact make it to market?